Oncology

Back to articles

Palbociclib: An emerging option for advanced breast cancer

KEY POINT

A recent study found that palbociclib (Ibrance—Pfizer) combined with fulvestrant (Faslodex—AstraZeneca) resulted in longer progression-free survival (PFS) in women with hormone receptor–positive (HR-positive), human epidermal growth factor 2 receptor (HER2)—negative relapsed or progressive metastatic breast cancer than fulvestrant alone.

SOURCES

Turner NC et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–19.

Carey LA et al. Palbociclib—taking breast-cancer cells out of gear [Editorial]. N Engl J Med. 2015;373:273–4.